-
A randomized, controlled trial of obese men, ages 35 to 55, with erectile dysfunction showed that weight loss and increased physical activity allowed 31% to regain sexual function and most reduced their cardiac risk factors.
-
Among patients with early, localized prostate cancer, the mortality rate accelerated after 15 years.
-
Current rofecoxib use was associated with a higher risk of acute myocardial infarction or admission for heart failure compared to celecoxib.
-
This report from multiple cooperating centers describes findings in 403 patients who presented with dysphagia and 140 patients with noncardiac chest pain and 44 patients with both symptoms on presentation.
-
This report by Song and colleagues used a validated food frequency questionnaire in 39,345 women from the Womens Health Study.
-
The FDA has approved the first once-a-week combined hormone therapy for postmenopausal symptoms.
-
How would you interpret the 12-lead ECG shown in the Figure? What is distinctly unusual about this tracing? What would you ask the technician who recorded this tracing?
-
Since the results of the Womens Health Initiative randomized trials, many fewer postmenopausal women are using estrogen to control hot flashes. Alternatives include progesterones, antidepressants in low doses, caffeine avoidance, exercise, phytoestrogens, and black cohosh.
-
In heterozygous familial hypercholesterolemia patients, rosuvastatin produced significantly greater reductions in LDL cholesterol, increases in HDL cholesterol, beneficial changes in other lipid values, and achievement of NCEP cholesterol goals than observed with equivalent doses of atorvastatin, with a similar adverse event profile.
-
The meta-analysis by Vink and colleagues demonstrates that patients with either aortic or mitral valve replacement will benefit from high-intensity VKA therapy.